sr13668
Small moleculeexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jun 1, 2009 (NCT00896207)
Timeline
2000s
- Jan 1, 2009
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Serine/threonine-protein kinase AKTINHIBITOR
AKT1 inhibitor
Compound is thought to be an Akt pathway inhibitor and inhibits Akt phosphorylation but does not bind to ATP-binding site (or any site?) on Akt kinases (PMID:17602463)
Chemistry & pharmacology
Loading structure…
SMILES
CCOC(=O)c1ccc2[nH]c3c(OC)c4[nH]c5ccc(C(=O)OCC)cc5c4cc3c2c1- Mol. weight
- 430.46 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3545143 ↗
- ChEMBLCHEMBL245030 ↗
Also known as
- sr13668
- sr13668
- sr13668
- sr 13668
- sr-13668
- sr-13668
- sr-13668
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00896207 | Phase 1 | Jun 1, 2009 | Mayo Clinic, National Cancer Institute (NCI) |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Mayo Clinic | Academic/Hospital | 1 | 0 | 1 | 2009 |
| National Cancer Institute (NCI) | Government | 1 | 1 | 1 | 2009 |
2 organizations
Page 1 / 1